Markus Moehler

Goethe University Frankfurt

Publishes on Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Esophageal Cancer Research and Treatment. 518 papers and 26k citations.

518Publications

26kTotal Citations

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Esophageal Cancer Research and Treatment Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al.|The Lancet|2021

Cited by 2.9kOpen Access

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al.|The Lancet|2019

Cited by 2.6kOpen Access

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al.|The Lancet Oncology|2014

Cited by 1.7k

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał et al.|New England Journal of Medicine|2021

Cited by 1.7kOpen Access

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018

Cited by 1.3kOpen Access